Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome-Coronavirus Spike Protein

被引:8
作者
Raadsen, Matthijs P. [1 ]
Dahlke, Christine [2 ,3 ,4 ]
Fathi, Anahita [2 ,3 ,4 ,5 ]
Lamers, Mart M. [1 ]
van den Doel, Petra [1 ]
Zaeck, Luca M. [1 ]
van Royen, Martin E. [6 ]
de Bruin, Erwin [1 ,7 ]
Sikkema, Reina [1 ]
Koopmans, Marion [1 ]
van Gorp, Eric C. M. [1 ]
Sutter, Gerd [8 ,9 ]
de Vries, Rory D. [1 ]
Addo, Marylyn M. [2 ,3 ,4 ,5 ,11 ]
Haagmans, Bart L. [1 ,10 ]
机构
[1] Erasmus MC, Dept Virosci, Rotterdam, Netherlands
[2] Univ Med Ctr Hamburg Eppendorf, Inst Infect Res & Vaccine Dev IIRVD, Hamburg, Germany
[3] Bernhard Nocht Inst Trop Med, Dept Clin Immunol Infect Dis, Hamburg, Germany
[4] German Ctr Infect Res, Partner site Hamburg Lubeck Borstel Riems, Hamburg, Germany
[5] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Div Infect Dis, Hamburg, Germany
[6] Erasmus MC, Dept Pathol, Rotterdam, Netherlands
[7] Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Div Pathol, Utrecht, Netherlands
[8] LMU Univ Munich, Inst Infect Dis & Zoonoses, Div Virol, Munich, Germany
[9] German Ctr Infect Res, Partner Site Munich, Munich, Germany
[10] Erasmus MC, Dept Virosci, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
[11] Univ Med Ctr Hamburg Eppendorf, Inst Infect Res & Vaccine Dev IIRVD, Martinistr 52, D-20246 Hamburg, Germany
关键词
Middle East respiratory syndrome-related coronavirus; MPXV; MVA; modified vaccinia virus Ankara; monkeypox virus; IMMUNOGENICITY; EFFICACY; SAFETY;
D O I
10.1093/infdis/jiad052
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A modified vaccinia virus Ankara-based candidate vaccine against Middle East respiratory syndrome-associated coronavirus elicits monkeypox virus neutralizing antibodies after 3 doses in healthy clinical trial participants. Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)-associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.
引用
收藏
页码:586 / 590
页数:5
相关论文
共 15 条
  • [11] LOURIE B, 1972, B WORLD HEALTH ORGAN, V46, P633
  • [12] Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
    Pittman, Phillip R.
    Hahn, Matthew
    Lee, HeeChoon S.
    Koca, Craig
    Samy, Nathaly
    Schmidt, Darja
    Hornung, Joachim
    Weidenthaler, Heinz
    Heery, Christopher R.
    Meyer, Thomas P. H.
    Silbernagl, Guenter
    Maclennan, Jane
    Chaplin, Paul
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (20) : 1897 - 1908
  • [13] Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development
    Volz, A.
    Sutter, G.
    [J]. ADVANCES IN VIRUS RESEARCH, VOL 97, 2017, 97 : 187 - 243
  • [14] Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
    Weskamm, Leonie M.
    Fathi, Anahita
    Raadsen, Matthijs P.
    Mykytyn, Anna Z.
    Koch, Till
    Spohn, Michael
    Friedrich, Monika
    MVA MERS S Study Grp, Bart L.
    Haagmans, Bart L.
    Becker, Stephan
    Sutter, Gerd
    Dahlke, Christine
    Addo, Marylyn M.
    [J]. CELL REPORTS MEDICINE, 2022, 3 (07)
  • [15] Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
    Zaeck, Luca M.
    Lamers, Mart M.
    Verstrepen, Babs E.
    Bestebroer, Theo M.
    van Royen, Martin E.
    Gotz, Hannelore
    Shamier, Marc C.
    van Leeuwen, Leanne P. M.
    Schmitz, Katharina S.
    Alblas, Kimberley
    van Efferen, Suzanne
    Bogers, Susanne
    Scherbeijn, Sandra
    Rimmelzwaan, Guus F.
    van Gorp, Eric C. M.
    Koopmans, Marion P. G.
    Haagmans, Bart L.
    GeurtsvanKessel, Corine H.
    de Vries, Rory D.
    [J]. NATURE MEDICINE, 2023, 29 (01) : 270 - +